Liver Cancer Drugs Market Analysis

Liver Cancer Drugs Market Analysis

To get key market trends

  Download Free Sample

Based on the type, the market is categorized into hepatocellular carcinoma (HCC), cholangiocarcinoma, hepatoblastoma, liver metastasis, and other types. The HCC segment is set to lead the market, generating the highest revenue of USD 1.9 billion, with projections to reach USD 5 billion by 2032.
 

• The high market growth is due to its prevalence among individuals with chronic liver diseases such as cirrhosis. The slow progression in the early stages offered a window for potential cures with appropriate treatment, driving significant demand for effective therapeutics.
   
• For instance, recent advancements such as the combination of PDL1 blockade with atezolizumab and VEGF blockade with bevacizumab, showcased promising outcomes in treating advanced HCC. Similarly, the Nature Journal article from April 2021 highlighted the integration of immunotherapy with local interventions. Thus, the emergence of various therapies for HCC has intensified R&D efforts, thereby bolstering the market expansion.
   

Based on drug class, the liver cancer drugs market is classified into chemotherapeutic agents, targeted therapy drugs, and immunotherapy drugs. The targeted therapy drugs segment holds the largest market share of 53.9% in 2023.
 

• This segment is expected to dominate the market due to its effectiveness compared to conventional chemotherapy. The focus on genome-targeted therapy, utilizing liver cancer drugs tailored to an individual's genetic composition, has significantly advanced the field of liver cancer treatment.
   
• For instance, according to European Society for Medical Oncology (ESMO), genome-targeted therapy, that tailors treatments to an individual's genetic profile, has shown remarkable progress in recent years. In 2018, the response rate of the targeted therapy was 5.48% that has reached to the estimated response rate climbing to 7% by 2020 marking a significant enhancement in treatment efficacy. This uptick suggested a greater proportion of patients undergoing personalized genomic interventions achieved favorable outcomes, instilling renewed optimism for more precise and efficacious treatments.
   
• Such advantages associated with targeted therapy will spur the market growth.
   

Based on route of administration, the liver cancer drugs market is segmented into oral and injectable. The injectable segment is expected to reach USD 5.4 billion by end of 2032.
 

• Injectable drugs offered advantages such as rapid onset of action, precise dosage delivery, and ease of administration. Also, they are preferred for conditions requiring immediate treatment or when oral administration is not feasible. With ongoing advancements in drug formulation and delivery technologies, the injectable segment is expected to maintain its dominance in the market.
   

Based on medication type, the liver cancer drugs market is segmented into generic and branded. In 2023, the branded segment asserted its dominance in the market and is expected to show robust CAGR of 11.6% through 2032.
 

• Branded medications have established themselves as standard-of-care treatments for liver cancer. These branded drugs offer targeted therapies, immunotherapies, and chemotherapy options that have demonstrated efficacy in treating hepatocellular carcinoma and other liver cancer types.
   
• Thus, aforementioned factors associated with branded type segment is expected to drive their prominence in the market.
   

Based on gender, the liver cancer drugs market is segmented into male and female. The male segment dominated the market accounting for the largest market revenue in 2023.
 

• The male segment has attributed its dominance to the higher incidence of liver cancer among men compared to women. Factors such as lifestyle habits, including alcohol consumption and smoking, as well as occupational exposures, contribute to the prominence. For instance, World Cancer Research Fund International ranked liver cancer as the 6th most prevalent cancer worldwide. Particularly, it is the 5th most common cancer in men and the 9th most common in women, with higher occurrence in males. This has witnessed the male segment's dominance in the market.
   

The U.S. dominated the North American liver cancer drugs market accounting for USD 1.1 billion in 2023 and is anticipated to show significant growth over the analysis period.
 

• The U.S. is expected to hold a significant share due to the high incidence of liver cancer emerging the need for treatment, early adoption of advanced diagnostic tests and therapies for liver cancer.
   
• For instance, according to the American Cancer Society, in 2023, over 41,000 people in the U.S. were estimated to be diagnosed with intrahepatic bile duct cancer and primary liver cancer. Liver cancer rates significantly increased, more than tripling since 1980. These statistics underscored the crucial need for ongoing research, enhanced prevention efforts, and improved treatment options to combat liver cancer and mitigate its impact.
   
• Furthermore, the presence of major pharmaceutical players and the launch of new products are few of the other driving factors that augment the country level market growth.
   

Germany exhibited a high growth potential in the European liver cancer drugs market.
 

• Germany’s well-established healthcare infrastructure supports advanced cancer treatment and widespread access to novel therapies. Also, strong focus on medical research and innovation, with numerous clinical trials and research projects dedicated to liver cancer witnessed country’s prominence in the market.
   

The Asia Pacific market for liver cancer drugs is poised witness 12.2% growth rate up to 2032.
 

• The Asia Pacific region presented a significant growth opportunities in the liver cancer drugs market due to the high prevalence of liver cancer in the region.
   
• According to the NCBI, liver cancer is the fifth most common cancer and the second leading cause of cancer-related deaths in Asia. In 2020, the region reported approximately 609,596 new liver cancer cases, accounting for around 72.5% of the global incidence, with an age-standardized rate (ASR) of 11.6 per 100,000. This significant burden underscored the critical need for advancements in liver cancer treatment and prevention in the Asia Pacific region.
   
• In addition, increased awareness, and implementation of screening programs for liver cancer are leading to earlier diagnosis and a higher demand for effective treatments further contributing to the region’s growth.